{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:47:44Z","timestamp":1791384464322,"version":"4.3.3"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.hlc.2023.09.005","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:45:27Z","timestamp":1715312727000},"page":"962-974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Systematic Review and Meta-Analysis of Randomised Controlled Trials Assessing Clinical and Haemodynamic Outcomes of Ivabradine in Heart Failure With Reduced Ejection Fraction Patients"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-2306","authenticated-orcid":false,"given":"Yoga","family":"Waranugraha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardian","family":"Rizal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cholid Tri","family":"Tjahjono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Yasmina","family":"Vilado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael Ibot","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikri","family":"Abudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwi Ayu","family":"Setyaningrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.hlc.2023.09.005_bib1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/eurheartj\/ehu440","article-title":"Heart rate in chronic heart failure: an overlooked risk factor","volume":"36","author":"Komajda","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hlc.2023.09.005_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0895-7061(99)00252-6","article-title":"Risk stratification in hypertension: new insights from the Framingham study","volume":"13","author":"Kannel","year":"2000","journal-title":"Am J Hypertens"},{"issue":"9744","key":"10.1016\/j.hlc.2023.09.005_bib3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"TLancet"},{"issue":"36","key":"10.1016\/j.hlc.2023.09.005_bib4","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.hlc.2023.09.005_bib5","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9146","key":"10.1016\/j.hlc.2023.09.005_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"9169","key":"10.1016\/j.hlc.2023.09.005_bib7","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.hlc.2023.09.005_bib8","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hlc.2023.09.005_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hlc.2023.09.005_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ehjcvp\/pvy011","article-title":"Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction","volume":"5","author":"Ibrahim","year":"2019","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"issue":"16","key":"10.1016\/j.hlc.2023.09.005_bib11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","article-title":"Heart Rate Lowering by Specific and Selective If Current Inhibition with Ivabradine: A New Therapeutic Perspective in Cardiovascular Disease","volume":"64","author":"DiFrancesco","year":"2004","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.hlc.2023.09.005_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/clc.23581","article-title":"Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials","volume":"44","author":"Bryan Richard","year":"2021","journal-title":"Clin Cardiol"},{"issue":"10","key":"10.1016\/j.hlc.2023.09.005_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/clc.22578","article-title":"The Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta-analysis With Trial Sequential Analysis of More Than 40000 Patients","volume":"39","author":"Tanbo\u011fa","year":"2016","journal-title":"Clin Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2023.09.005_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12872-017-0540-3","article-title":"Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials","volume":"17","author":"Mengesha","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.hlc.2023.09.005_bib15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.hlc.2023.09.005_bib16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/1524839919893361","article-title":"A\u00a0Review of the PubMed PICO Tool: Using Evidence-Based Practice in Health Education","volume":"21","author":"Brown","year":"2020","journal-title":"Health Promot Pract"},{"key":"10.1016\/j.hlc.2023.09.005_bib17","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.hlc.2023.09.005_bib18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.hlc.2023.09.005_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.hlc.2023.09.005_bib20","series-title":"Modern Meta-Analysis: Review and Update of Methodologies","author":"Cleophas","year":"2017"},{"issue":"7414","key":"10.1016\/j.hlc.2023.09.005_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7584","key":"10.1016\/j.hlc.2023.09.005_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/bmj.39057.406644.68","article-title":"What is heterogeneity and is it important?","volume":"334","author":"Fletcher","year":"2007","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.hlc.2023.09.005_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ipej.2020.12.005","article-title":"The benefit of atrioventricular junction ablation for permanent atrial fibrillation and heart failure patients receiving cardiac resynchronization therapy: An updated systematic review and meta-analysis","volume":"21","author":"Waranugraha","year":"2021","journal-title":"Indian Pacing Electrophysiol J"},{"key":"10.1016\/j.hlc.2023.09.005_bib24","article-title":"Head-to-head comparison between left atrial appendage occlusion and non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: A systematic review and\u00a0meta-analysis study","author":"Waranugraha","year":"2023","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.hlc.2023.09.005_bib25","first-page":"298","article-title":"A\u00a0systematic review and meta-analysis of the direct comparison of second-generation cryoballoon ablation and contact force-sensing radiofrequency ablation in patients with paroxysmal atrial fibrillation","volume":"12","author":"Waranugraha","year":"2022","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.hlc.2023.09.005_bib26","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.15420\/aer.2021.37","article-title":"Prophylactic cavotricuspid isthmus ablation in atrial fibrillation without documented typical atrial flutter: A systematic review and meta-analysis","volume":"11","author":"Waranugraha","year":"2022","journal-title":"Arrhythmia Electrophysiol Rev"},{"issue":"1","key":"10.1016\/j.hlc.2023.09.005_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s43044-021-00194-1","article-title":"Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences","volume":"73","author":"Waranugraha","year":"2021","journal-title":"Egypt Heart J"},{"issue":"4","key":"10.1016\/j.hlc.2023.09.005_bib28","first-page":"975","article-title":"The superiority of high-power short-duration radiofrequency catheter ablation strategy for atrial fibrillation treatment: A systematic review and meta-analysis study","volume":"37","author":"Waranugraha","year":"2021","journal-title":"J\u00a0Arrhythmia"},{"issue":"2","key":"10.1016\/j.hlc.2023.09.005_bib29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial)","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int J Cardiol"},{"issue":"9641","key":"10.1016\/j.hlc.2023.09.005_bib30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.hlc.2023.09.005_bib31","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","article-title":"Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure \u2014 J-SHIFT Study\u2014","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.hlc.2023.09.005_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ehj.2011.09.001","article-title":"Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure","volume":"63","author":"Mansour","year":"2011","journal-title":"Egypt Heart J"},{"key":"10.1016\/j.hlc.2023.09.005_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2019.12.024","article-title":"PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial","volume":"223","author":"Mentz","year":"2020","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.hlc.2023.09.005_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1074248410370326","article-title":"Impact of \u2018\u201cOff-Label\u201d\u2019 Use of Ivabradine on Exercise Capacity, Gas Exchange, Functional Class, Quality of Life, and Neurohormonal Modulation in Patients With Ischemic Chronic Heart Failure","volume":"15","author":"Sarullo","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"issue":"9744","key":"10.1016\/j.hlc.2023.09.005_bib35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.hlc.2023.09.005_bib36","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2023.09.005_bib37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1253\/circj.CJ-15-1112","article-title":"Heart rate control with if inhibitor, ivabradine, in japanese patients with chronic heart failure \u2013 A randomized, double-blind, placebo-controlled phase II study","volume":"80","author":"Tsutsui","year":"2016","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.hlc.2023.09.005_bib38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jacc.2022.05.027","article-title":"Sustained-release ivabradine hemisulfate in patients with systolic heart failure","volume":"80","author":"Ye","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2023.09.005_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"issue":"4","key":"10.1016\/j.hlc.2023.09.005_bib40","first-page":"582","article-title":"Aggressive beta-blocker titration in stabilized acute heart failure patients with low left ventricular ejection fraction","volume":"16","author":"Waranugraha","year":"2021","journal-title":"J\u00a0Taibah Univ Med Sci"},{"issue":"21","key":"10.1016\/j.hlc.2023.09.005_bib41","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/CIRCULATIONAHA.115.018094","article-title":"Ivabradine: Role in the chronic heart failure armamentarium","volume":"133","author":"Psotka","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.hlc.2023.09.005_bib42","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: Beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.hlc.2023.09.005_bib43","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?","volume":"59","author":"Swedberg","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2023.09.005_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36628\/ijhf.2019.0009","article-title":"Optimization of heart failure treatment by heart rate reduction","volume":"2","author":"B\u00f6hm","year":"2020","journal-title":"Int J Heart Fail"},{"issue":"6","key":"10.1016\/j.hlc.2023.09.005_bib45","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s11096-018-0715-8","article-title":"The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis","volume":"40","author":"Hartmann","year":"2018","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"10.1016\/j.hlc.2023.09.005_bib46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.15420\/aer.2019.30.2","article-title":"Ivabradine and AF: Coincidence, correlation or a new treatment?","volume":"8","author":"Abdelnabi","year":"2020","journal-title":"Arrhythmia Electrophysiol Rev"},{"issue":"4","key":"10.1016\/j.hlc.2023.09.005_bib47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1074248415624157","article-title":"Ivabradine: Heart failure and beyond","volume":"21","author":"Chaudhary","year":"2016","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.hlc.2023.09.005_bib48","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jce.12974","article-title":"Atrial fibrillation after coronary artery bypass surgery: Can ivabradine reduce its occurrence?: Ivabradine in postoperative atrial fibrillation","volume":"27","author":"Abdel-Salam","year":"2016","journal-title":"j Cardiovasc Electrophysiol"},{"issue":"1-2","key":"10.1016\/j.hlc.2023.09.005_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40119-013-0024-1","article-title":"Ivabradine versus beta-blockers in patients with conduction abnormalities or left ventricular dysfunction undergoing cardiac surgery","volume":"3","author":"Iliuta","year":"2014","journal-title":"Cardiol Ther"},{"issue":"12","key":"10.1016\/j.hlc.2023.09.005_bib50","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2020.10.005","article-title":"Effects of ivabradine on cardiac remodeling in patients with stable symptomatic heart failure: A systematic review and meta-analysis","volume":"42","author":"Wan","year":"2020","journal-title":"Clin Ther"},{"issue":"13","key":"10.1016\/j.hlc.2023.09.005_bib51","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.CIR.0000118464.48959.1C","article-title":"Long-term heart rate reduction induced by the selective I f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure","volume":"109","author":"Mulder","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hlc.2023.09.005_bib52","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ejhf.2486","article-title":"The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF","volume":"24","author":"DeVore","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623043184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623043184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:46:39Z","timestamp":1721342799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950623043184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1443950623043184"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2023.09.005","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review and Meta-Analysis of Randomised Controlled Trials Assessing Clinical and Haemodynamic Outcomes of Ivabradine in Heart Failure With Reduced Ejection Fraction Patients","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2023.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}